The CE-IVD marked panel helps clinicians identify the root cause of an infection and swiftly provide the most suitable treatment for patients.
Validated and registered under the In Vitro Diagnostic Device Directive (IVDD) in May, the new panel uses polymerase chain reaction (PCR) technology to detect a range of common GI bacteria in stool samples.
The bacteria include Shigella spp/enteroinvasive E coli (EIEC), Salmonella spp, Campylobacter jejuni, Campylobacter coli and Campylobacter upsaliensis.
The test can produce results in approximately two hours with specificity and sensitivity of more than 98%.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Thermo Fisher Scientific Genetic Testing Solutions senior medical director Dr Manoj Gandhi said: “The TaqPath Enteric Bacterial Select Panel’s ability to identify and differentiate between the most common diarrhoea-causing pathogens will make testing more accessible and provide laboratorians with more agility when identifying GI bacteria.
“Detecting these different pathogens in a single test can preserve precious lab resources while still providing clinicians critical information needed to make the right treatment decisions for their patients.”
Using the TaqPath Enteric Bacterial Select Panel, testing can be performed in a single test tube and scaled up to accommodate testing of 93 samples in a single run.
In August, Thermo Fisher Scientific introduced the CE-IVD (IVDD) Oncomine Dx Express Test and Oncomine Reporter Dx for use in clinical laboratories.
The Oncomine Dx Express Test has been designed to identify deletions, insertions, substitutions and copy number gain present in 42 genes, along with fusions or splicing variants in 18 genes, from DNA and RNA in formalin-fixed paraffin-embedded tumour tissue samples of solid malignant neoplasms.